MedPath

Cephalexin

CEPHALEXIN CAPSULES, USP

Approved
Approval ID

7b52fd9a-3cb6-4f0e-9e45-17a1eaec926d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 18, 2022

Manufacturers
FDA

Bi-Coastal Pharma International LLC

DUNS: 078397428

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cephalexin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code42582-212
Application NumberANDA062713
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cephalexin
Product Specifications
Route of AdministrationORAL
Effective DateMarch 3, 2020
FDA Product Classification

INGREDIENTS (6)

CEPHALEXINActive
Quantity: 500 mg in 1 1
Code: OBN7UDS42Y
Classification: ACTIM
ANHYDROUS LACTOSEInactive
Code: 3SY5LH9PMK
Classification: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT

Cephalexin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code42582-211
Application NumberANDA062713
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cephalexin
Product Specifications
Route of AdministrationORAL
Effective DateMarch 3, 2020
FDA Product Classification

INGREDIENTS (6)

CEPHALEXINActive
Quantity: 250 mg in 1 1
Code: OBN7UDS42Y
Classification: ACTIM
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
ANHYDROUS LACTOSEInactive
Code: 3SY5LH9PMK
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.